GlassScriptPhysician profile
Subbarao Gorti
NPI 1356399075
$4,087.98
in general payments reported to CMS, 2019-2025
24 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $287 · 2021: $705 · 2022: $798 · 2023: $868 · 2024: $714 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.62 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $647.94 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $633.10 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $283.77 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Exact Sciences Corporation | $248.91 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $190.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $133.86 | 2019 | |
| Pfizer INC. | $123.62 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $78.09 | 2021-2025 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.93 | 2019-2023 | |
| Amgen INC. | $66.90 | 2024-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $59.80 | 2022-2023 | |
| Glaxosmithkline, LLC. | $55.94 | 2019-2023 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $47.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $44.04 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $36.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.18 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $33.34 | 2019-2023 | |
| Astellas Pharma US INC | $33.27 | 2019 | |
| Becton, Dickinson and Company | $25.62 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.66 | 2023 | Linzess |
| Allergan, INC. | $16.89 | 2020 | |
| Sanofi Pasteur INC. | $13.49 | 2019 | |
| Esperion Therapeutics, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subbarao Gorti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.